Alexion's Kanuma Fails To Impress NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, says it is not recommending Alexion's Kanuma (sebelipase alfa) for one set of patients with lysosomal acid lipase deficiency, but wants more evidence when considering another group of patients with the same rare genetic disorder. The institute is concerned that the drug is not good value for the National Health Service, while Alexion says NICE has failed to recognize the Kanuma's "transformative innovation."
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.